Amantadine

2022-09-16:

Amantadine #

• Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine
  • Amantadine is currently the only drug proven to alleviate LID (levoDOPA-induced dyskinesia)
  • Amantadine preferentially blocks inward-rectifying K+ channel type 2 (Kir2) channels in striatal spiny projection neurons (SPNs) — not NMDA receptors. In so doing, amantadine enhances dendritic integration of excitatory synaptic potentials in SPNs and enhances — not antagonizes — the induction of long-term potentiation (LTP) at excitatory, axospinous synapses.
  • Prolonged elevation of striatal DA (subsequent to levodopa treatment) promotes the induction of long-term potentiation (LTP) of glutamatergic synapses on direct-pathway spiny projection neurons (dSPNs). Unlike the situation in the normal brain where DA sculpts striatal action selection circuitry in response to experience, the levoDOPA-induced elevation is disconnected from experience, disrupting normal patterns of connectivity.
• Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial Equal efficacy to Methylphenidate!
• Dopaminergic